CE Mark awarded to anti-CCP diagnostic kit
A diagnostic kit for rheumatoid arthritis has been given a CE Mark.
An anti-cyclic citrullinated peptides (anti-CCP) diagnostic kit for rheumatoid arthritis has been given the CE Mark of approval, Theradiag announced today (April 23rd).
This in-vitro test adds to the theranostic specialist's Fidis portfolio of equipment for auto-immunes diseases, with the technology expected to bring down the time and cost of analysis.
According to the company, this new method of uncovering anti-CCP antibodies provides a reliable detection of severe forms of rheumatoid arthritis at more rapid dosing and at a lower price than existing equipment.
It marks the third proprietary diagnostic kit of Theradiag to be offered a CE Mark this year, with the auto-immune diseases segment growing in 2012 and sparking a 17 per cent increase for its Fidis products.
"With this new addition to the Fidis range we position ourselves as testing and monitoring leaders in auto-immune and inflammatory diseases," said Michel Finance, chief executive of Theradiag.
A statement from the company revealed the auto-immune diseases segment made up 43 per cent of its total company sales last year.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...